PUBLICATION

Augmentation of Pectoral Fin Teratogenicity by Thalidomide in Human Cytochrome P450 3A-Expressing Zebrafish

Authors
Dong, W., Akasaka, I., Komiyama, A., Nakamura, T., Mizoguchi, N., Nawaji, T., Ikushiro, S., Kobayashi, M., Teraoka, H.
ID
ZDB-PUB-230330-55
Date
2023
Source
Pharmaceuticals (Basel, Switzerland)   16(3): (Journal)
Registered Authors
Kobayashi, Makoto, Teraoka, Hiroki
Keywords
CYP1A1, CYP3A4, CYP3A7, human, teratogenicity, thalidomide, zebrafish
MeSH Terms
none
PubMed
36986467 Full text @ Pharmaceuticals (Basel)
Abstract
The pharmacological and toxicological effects of active metabolites of enzymes including cytochrome P450 (CYP) are important. While it has been believed for a long time that thalidomide causes characteristic limb malformation only in rabbits and primates including humans, the involvement of their CYP3A subtypes (CYP3As) has been suggested. Recently, however, it was reported that zebrafish were sensitive to thalidomide, showing defects of pectoral fins, homologous organs of forelimbs in mammals, as well as other deformities. In this study, we prepared human CYP3A7 (hCYP3A7)-expressing zebrafish (F0) using a transposon system. Thalidomide caused pectoral fin defects and other malformations including pericardial edema in hCYP3A7-expressing embryos/larvae but not in wild-type and hCYP1A1-expressing embryos/larvae. Thalidomide also reduced the expression of fibroblast growth factor 8 in pectoral fin buds in only hCYP3A7-expressing embryos/larvae. The results suggest the involvement of human-type CYP3A in thalidomide teratogenicity.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping